The transmembrane domain of podoplanin is known to bind to CD9 and CD44, which plays a role in cancer progression and lymph node expansion during adaptive immune activation (Nakazawa et al., 2008; Martín-Villar et al., 2010). The gene discussed is PDPN; the disease is cancer.